Economics & Pharmacy Practice
Department of Economics
2133 Faculty Administration Bldg (FAB)
656 W. Kirby St.
Detroit, MI 48202
Department of Pharmacy Practice
259 Mack Avenue, Suite 2122
Detroit, MI 48201
Degrees and Certifications
- Ph.D., Health Policy (Economics), Harvard University, Cambridge, MA (2011)
- M.A., Economics, University of Toronto, Toronto, ON (2001)
- B.Sc., Mathematics and Economics, University of Toronto, Toronto, ON (2000)
Positions and Employment
- 2019-present: Assistant Professor, Department of Economics, Wayne State University
- 2019-present: Assistant Professor, Department of Pharmacy Practice, Wayne State University
- 2011-2019: Assistant Professor, Department of Public Health Sciences, University of Chicago
- 2012-2019: Faculty Affiliate, Center for Health and the Social Sciences, University of Chicago
- 2012-2019: Member, University of Chicago Comprehensive Cancer Center
- 2014- present: Alliance for Clinical Trials in Oncology: Member of Cancer Care Delivery Research, Symptom Intervention, Health Outcomes, Prevention, Community Oncology, Health Disparities, and Cancer in the Older Adult Committees
Primary Research Interest
Fabrice Smieliauskas is a health economist in the Department of Economics and the Department of Pharmacy Practice at Wayne State University. His economic and health services research on pharmaceuticals and medical devices in cancer and surgery addresses questions requiring a cross-disciplinary marriage of rigorous economic methods with biological and clinical knowledge. This work falls under three main themes: 1) determining the costs and value of medical technologies and procedures; 2) advancing the field of implementation science in health care; 3) analyzing the effects of public policy and regulation on the biomedical research enterprise.
Refereed Journal Articles
Witiw, C. D., F. Smieliauskas, S. Ham, V.C. Treynelis. 2020. Cervical Disc Replacement: “Real-world” Utilization of an Emerging Technology. In press, Journal of Neurosurgery: Spine.
Uppal, A., F. Smieliauskas, S. Maron, M. Sharma, B. Polite, M.C. Posner, K. Turaga. 2020. Facilities that Service Economically Advantaged Neighborhoods Perform Surgical Metastasectomy More Often for Patients with Colorectal Liver Metastases. Cancer. 126(2):281-292. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32529.
Sharma, H., R.T. Konetzka, F. Smieliauskas. 2019. The Relationship Between Reported Staffing and Expenditures in Nursing Homes. Medical Care Research and Review. 76(2):758-783. http://journals.sagepub.com/doi/10.1177/1077558717739214.
Dong, J., F. Smieliauskas, R. T. Konetzka. 2019. Effects of Long-Term Care Insurance on Financial Well-being. The Geneva Papers on Risk and Insurance – Issues and Practice. 44(2):277-302. https://link.springer.com/article/10.1057/s41288-018-00113-7.
Pandey, K.R., F. Yang, K.A. Cagney, F. Smieliauskas, D.O. Meltzer, G.W. Ruhnke. 2019. The impact of marital status on health care utilization among Medicare beneficiaries. Medicine. 98(12):e14871. https://insights.ovid.com/pubmed?pmid=30896632.
Witiw, C. D., F. Smieliauskas, J. O’Toole, M. Fehlings, R. Fessler. 2019. Comparison of anterior cervical discectomy and fusion to posterior cervical foraminotomy for cervical radiculopathy: utilization, costs and adverse events 2003 – 2014. Neurosurgery. 84(2):413-420. https://academic.oup.com/neurosurgery/article/84/2/413/4934773.
Smieliauskas, F., H. Sharma, C. Hurley, J. De Souza, Y.-C. T. Shih. 2018. State insurance mandates and off-label use of chemotherapy. Health Economics. 27(1):e55-e70. http://onlinelibrary.wiley.com.proxy.uchicago.edu/doi/10.1002/hec.3537/abstract.
Witiw, C.D., F. Smieliauskas, M.G. Fehlings. 2018. Health Economics and the Management of Degenerative Cervical Myelopathy. Neurosurgery Clinics of North America. 29(1):169-176. https://www.sciencedirect.com/science/article/pii/S1042368017301092.
Shih, Y.C.-T., Y. Xu, L. Liu, F. Smieliauskas. 2017. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. Journal of Clinical Oncology. 35(22):2482-89. http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3742.
Witiw, C.D., L.A. Tetreault, F. Smieliauskas, B. Kopjar, E.M. Massicotte, M.G. Fehlings. 2017. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation. The Spine Journal. 17(1):15-25. http://www.sciencedirect.com/science/article/pii/S1529943016310221.
Smieliauskas, F. 2016. Capsule Commentary on Wolf et al., A Patient-Centered Prescription Drug Label to Promote Appropriate Medication Use and Adherence. Journal of General Internal Medicine. 31(12):1507. http://link.springer.com/article/10.1007%2Fs11606-016-3854-4.
Smieliauskas, F. 2016. Conflicts of interest in medical technology markets: evidence from orthopedic surgery. Health Economics. 25(6):723-39. http://onlinelibrary.wiley.com/doi/10.1002/hec.3177/full.
Wong, R.H., F. Smieliauskas, I.-W. Pan, S.K. Lam. 2015. Interrupted Time Series. Analysis: Studying Trends in Neurosurgery. Neurosurgical Focus 39(6):E6. http://thejns.org/doi/abs/10.3171/2015.9.FOCUS15374.
Shih, Y.-C. T.*, F. Smieliauskas*, D.M. Geynisman, R.J. Kelly, T.J. Smith. 2015. Trends in the costs and utilization of targeted cancer therapies for the privately insured non-elderly: 2001-2011. Journal of Clinical Oncology. 33(19):2190-6. http://jco.ascopubs.org/content/33/19/2190.
Smieliauskas, F., H. MacMahon, R. Salgia, Y.-C. T. Shih. 2014. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. Journal of Medical Screening. 21(4):207-15. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407799.
Geynisman, D.M.*, C.-R. Chien*, F. Smieliauskas, C. Shen, Y.-C. T. Shih. 2014. Economic Evaluation of Therapeutic Cancer Vaccines and Immunotherapy: a Systematic Review. Human Vaccines & Immunotherapeutics. 10(11):3415-24. http://www.tandfonline.com/doi/full/10.4161/hv.29407.
Smieliauskas, F., S. Lam, D. Howard. 2014. Impact of negative clinical trial results for vertebroplasty on vertebral augmentation procedure rates. Journal of the American College of Surgeons. 219(3):525-533.e1. http://www.sciencedirect.com/science/article/pii/S1072751514003573/.
Smieliauskas, F. *, C.-R. Chien*, C. Shen, D. M. Geynisman, Y.-C. T. Shih. 2014. Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review. Pharmacoeconomics. 32(7):651-80. http://link.springer.com/article/10.1007/s40273-014-0160-z.
Shen, C., C.-R. Chien, D. M. Geynisman, F. Smieliauskas, Y.-C. T. Shih. 2014. A Review of Economic Impact of Targeted Oral Anticancer Medications. Expert Review of Pharmacoeconomics and Outcomes Research. 14(1):45-69. http://informahealthcare.com/eprint/TmT2rwDs8WVZUpIqDysv/full/.
Shih Y.-C. T., Y. Xu, W. Dong, F. Smieliauskas, S. Giordano, Y. Shen. 2014. First Do No Harm: Population-Based Study Shows Non-Evidence-Based Trastuzumab Prescription May Harm Elderly Women with Breast Cancer. Breast Cancer Research and Treatment. 144(2):417-25. http://link.springer.com/article/10.1007%2Fs10549-014-2874-1.
President’s Cancer Panel. 2018. Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. A Report to the President of the United States from the President’s Cancer Panel. Bethesda (MD): President’s Cancer Panel. https://prescancerpanel.cancer.gov/report/drugvalue/. My research presented in the report.
National Academies of Sciences, Engineering and Medicine. 2016. Implementation of lung cancer screening: Proceedings of a workshop. Washington, DC: The National Academies Press. doi: 10.172216/23680. https://www.nap.edu/catalog/23680/implementation-of-lung-cancer-screening-proceedings-of-a-workshop. My research presented in the report.
Felt-Lisk, S., G. Mays, L. Harris, M. Lee, R. Nyman, and F. Smieliauskas. 2014. Evaluation of HRSA’s Clinical Pharmacy Demonstration Projects. Princeton, NJ: Mathematica Policy Research.
Chollet, D., R. Nyman, and F. Smieliauskas. 2004. Factors That Drive Health Care Costs in Indiana. Princeton, NJ: Mathematica Policy Research.
Verdier, J., S. Felt-Lisk, F. Smieliauskas, J. Wong, and L. Felland. 2004. Quality-Related Provider and Member Incentives in Medicaid Managed Care Organizations. Princeton, NJ: Mathematica Policy Research.
Chollet, D., F. Smieliauskas, and M. Konig. 2013. Mapping Health Insurance Markets, 2001: Structure and Change. Princeton, NJ: Mathematica Policy Research. http://www.statecoverage.org/files/Mapping%20State%20Health%20Insurance%20Markets%202001%20-%20Structure%20and%20Change.pdf.
Graff, S. 2017. Slow Uptake of Screening for Lung Cancer Highlights Obstacles. Journal of the National Cancer Institute. 109(4):1-2. https://academic.oup.com/jnci/article-abstract/109/4/1/3611012/Slow-Uptake-of-Screening-for-Lung-Cancer
For 2015 Journal of Clinical Oncology paper, “Trends in the costs and utilization of targeted cancer therapies”: American Health & Drug Benefits, Targeted Oncology, Science Life, Specialty Pharmacy News.
- 8/19-7/25: NCI UG1 CA189823. PI: J. Buckner. My role: co-I. “Alliance NCORP Research Base”.
- 12/18–11/23: NCI R01 CA225647. PI: Y.-C. T. Shih. My role: co-I. “Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications”.
- 11/17–3/20: NCI P30 CA014599. PI: M. Le Beau. My role: co-I. “No Smoker Left Behind.”
- 9/14–6/19: NCI UG1 CA189823. PI: J. Buckner. My role: co-I. “Alliance NCORP Research Base”.
- 3/16–1/18: NCATS UL1 TR000430. PI: F. Smieliauskas. My role: PI. “A Comparison of Single Level Anterior Cervical Discectomy and Fusion to Posterior Cervical Foraminotomy in the Treatment of Cervical Radiculopathy: A National Perspective with Long Term Follow-up.”
- 1/16–12/17: CHAS Seed Award. PI: F.Smieliauskas. My role: PI. “Racial disparities in Predictive Biomarkers, Access to Precision Medicine, and Cancer Outcomes”.
- 4/14–3/16: NCI R03 CA184986. PI: F. Smieliauskas. My role: PI. “Capacity constraints and disparities in the scale-up of lung cancer CT screening”.
- 1/13–6/15: Cancer Research Foundation Young Investigator Award. PI: F. Smieliauskas. My role: PI. Title: "Off-label Drug Use in Oncology: Policy, Unintended Consequences, and Comparative Effectiveness".
- 8/13–7/14: AHRQ R01 HS018535. PI: Y.-C. T. Shih. My role: Co-Investigator. Title: “Monoclonal Antibodies in Cancer Care: Is Underinsurance an Access Barrier?”.
- 12/12–2/14: ACS #IRG 58-004. PI: F. Smieliauskas. My role: PI. Title: "Off-label drug use in oncology: policy and unintended consequences for clinical research".
- 12/11–11/12: ACS #IRG 58-004. PI: F. Smieliauskas. My role: PI. Title: "The role of sponsorship in clinical oncology research: evidence from clinicaltrials.gov".
- 5/11–4/14: NIH U01 GM087729. PI: D. Lauderdale. My role: Co-Investigator. Title: “Modeling MRSA in the Community”.
- 7/07–6/10: NIH T32 AG00186. PI: D. Wise. My role: Pre-Doctoral Fellow in Health & Aging at the National Bureau of Economic Research.
- 9/07–8/09: SSHRC Doctoral Fellowship.
- 9/05–8/06: AHRQ T32 HS000055. PI: J. Newhouse. My role: Doctoral Fellow.
- 2018-present: International Society for Pharmacoeconomics and Outcomes Research
- 2018-present: Society for Medical Decision Making
- 2014-present: American Society of Clinical Oncology
- 2011, 2015, 2018-present: American Economic Association
- 2008-present: American Society of Health Economists
Departmental / University Service
- 2019-present: Undergraduate Committee, Department of Economics, Wayne State University
Editor / Reviewer
- 2019-present: Editorial Board, Medical Care Research and Review
- 2014: Full grant proposal reviewer, Robert Wood Johnson Foundation’s (RWJF) Public Health Services and Systems Research (PHSSR) program
- 2010-present: Referee for Journal of Health Economics, Pharmacoeconomics, Value in Health, Health Services Research, Medical Care Research and Review, Journal of the National Cancer Institute, Journal of the National Cancer Institute: Spectrum, The Oncologist, Journal of General Internal Medicine, Management Science